(Q37508524)

20 August 2017

1 reference

title

Protein C in critical illness (English)

1 reference

20 August 2017

Henry J Mann

1

1 reference

PubMed ID

19498123

20 August 2017

Mary A Short

series ordinal

2

1 reference

PubMed ID

19498123

20 August 2017

Douglas E Schlichting

series ordinal

3

1 reference

20 August 2017

1 June 2009

1 reference

American Journal of Health-System Pharmacy

20 August 2017

1 reference

20 August 2017

66

1 reference

20 August 2017

12

1 reference

20 August 2017

1089-1096

1 reference

Efficacy and safety of recombinant human activated protein C for severe sepsis

20 August 2017

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080276

Endothelial barrier protection by activated protein C through PAR1-dependent sphingosine 1-phosphate receptor-1 crossactivation

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080276

Protein C inhibitor secreted from activated platelets efficiently inhibits activated protein C on phosphatidylethanolamine of platelet membrane and microvesicles

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080276

The role of the endothelium in severe sepsis and multiple organ dysfunction syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080276

Protein C levels as a prognostic indicator of outcome in sepsis and related diseases

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080276

Prognostic value of protein C concentrations in neutropenic patients at high risk of severe septic complications

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080276

Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C, and protein S deficiencies

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080276

Time course of hemostatic abnormalities in sepsis and its relation to outcome.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080276

Multiple organ dysfunction syndrome in bone marrow transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080276

Changes of the hemostatic network in critically ill patients--is there a difference between sepsis, trauma, and neurosurgery patients?

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080276

Low levels of protein C are associated with poor outcome in severe sepsis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080276

Severe protein C deficiency predicts early death in severe sepsis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080276

Protein C concentrations in severe sepsis: an early directional change in plasma levels predicts outcome

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080276

Protein C Concentrations Correlate with Organ Dysfunction and Predict Outcome Independent of the Presence of Sepsis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080276

Protein C: a potential biomarker in severe sepsis and a possible tool for monitoring treatment with drotrecogin alfa (activated)

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080276

From bench to bedside: a review of the clinical trial development plan of drotrecogin alfa (activated).

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080276

Genetic and environmental influences on premature death in adult adoptees

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080276

Genetics of susceptibility to human infectious disease

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080276

A systematic review of the quality of genetic association studies in human sepsis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080276

Genetic risk factors for venous thrombosis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080276

Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: Further evidence for survival and safety and implications for early treatment*

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080276

Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080276

Pharmacokinetic-pharmacodynamic analysis of drotrecogin alfa (activated) in patients with severe sepsis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080276

Aging-associated changes in indices of thrombin generation and protein C activation in humans. Normative Aging Study

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080276

Drotrecogin alfa (activated) (recombinant human activated protein C) reduces host coagulopathy response in patients with severe sepsis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080276

Management of patients with severe sepsis, treated by drotrecogin alfa (activated).

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080276

31 March 2020

Identifiers

DOI

10.2146/AJHP080276

1 reference

20 August 2017

1 reference

PubMed ID

19498123